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Abstract
Background: The majority of individuals with acute myeloid leukemia (AML) respond to initial chemotherapy and
achieve a complete remission, yet only a minority experience long-term survival because a large proportion of patients
eventually relapse with therapy-resistant disease. Relapse therefore represents a central problem in the treatment of
AML. Despite this, and in contrast to the extensive knowledge about the molecular events underlying the process of
leukemogenesis, information about the mechanisms leading to therapy resistance and relapse is still limited.
Purpose and content of review: Recently, a number of studies have aimed to fill this gap and provided valuable
information about the clonal composition and evolution of leukemic cell populations during the course of disease, and
about genetic, epigenetic, and gene expression changes associated with relapse. In this review, these studies are
summarized and discussed, and the data reported in them are compiled in order to provide a resource for the
identification of molecular aberrations recurrently acquired at, and thus potentially contributing to, disease recurrence
and the associated therapy resistance. This survey indeed uncovered genetic aberrations with known associations with
therapy resistance that were newly gained at relapse in a subset of patients. Furthermore, the expression of a number
of protein coding and microRNA genes was reported to change between diagnosis and relapse in a statistically
significant manner.
Conclusions: Together, these findings foster the expectation that future studies on larger and more homogeneous
patient cohorts will uncover pathways that are robustly associated with relapse, thus representing potential targets for
rationally designed therapies that may improve the treatment of patients with relapsed AML, or even facilitate the
prevention of relapse in the first place.
Keywords: Acute myeloid leukemia, Relapse, Therapy resistance, Clonal evolution, Cytogenetics, Copy number
variation, Single nucleotide variants, DNA methylation, Gene expression profiling
Background
Acute myeloid leukemia (AML) is a malignant disease of
hematopoietic stem and progenitor cells (HSPCs) with a
median age of onset of around 67 years and an annual
incidence of 3–8/100.000 [1–4]. It is characterized by
the accumulation of immature blasts at the expense of
normal, functional myeloid cells in the bone marrow
and peripheral blood of affected patients. Standard induc-
tion chemotherapy, based on cytosine arabinoside and an
anthracycline like daunorubicin or idarubicin, leads to
complete remissions (CRs) in 40 to >90% of cases, de-
pending on patient age and the presence or absence of
specific somatically acquired genetic alterations [1–6].
Together with post-remission therapy (additional chemo-
therapy and/or hematopoietic stem cell transplantation),
5-year survival rates of <5–20 and >40% are achieved for
patients older and younger than 60 years, respectively
[1–4, 7]. Patients with acute promyelocytic leukemia
(APL), which is driven by fusion proteins involving the
retinoic acid receptor alpha (RARA), fare substantially
better than other patients with AML: in response to
targeted therapy based on all-trans retinoic acid, com-
bined with cytosine arabinoside or arsenic trioxide, they
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achieve CR and long-term remission rates of >90 and >80%,
respectively [8, 9].
The discrepancy between the favorable primary response
rates and the substantially lower long-term survival rates in
AML is due to the fact that a high proportion of patients
who achieve CR eventually relapse [2, 5, 6]. Even though
second and even third remissions may be achieved, these
are of progressively shorter duration, and cure is rarely ac-
complished. Relapse, and the associated resistance to cur-
rently available therapies, therefore represents one of the
central problems in the treatment of AML [2, 6, 7, 10].
Similar to normal hematopoiesis, leukemic hematopoiesis
is organized in a hierarchical manner. The bulk of the
leukemic cell mass is derived from mostly quiescent
leukemic stem cells (LSCs), which can divide either
symmetrically to produce two stem cells, or asymmet-
rically to give rise to one stem cell and one more differ-
entiated progenitor cell [11, 12]. The transforming
events giving rise to an LSC may take place either in a
hematopoietic stem cell (HSC), or in a progenitor cell
that consequently regains stem cell characteristics [11, 12].
Like their healthy counterparts, LSCs reside in the bone
marrow niche, and interactions with stromal cells in
this niche promote LSC dormancy and protection from
chemotherapy [11, 12]. The frequency of LSCs is mea-
sured mainly through transplantation experiments; esti-
mates range from 1 in 500 to 1 in 107 cells, depending
both on experimental variables and on leukemia-
intrinsic factors. In agreement with LSCs representing a
bastion of therapy resistance and a potential source of
relapse, high LSC frequencies, as well as the presence
of a stem cell expression signature, correlate with infer-
ior outcome in AML [11–13]. On the other hand, since
up to 40% of patients with AML are cured by conven-
tional therapies, LSCs are not resistant to these in all
cases. A variety of different and only partially explored
factors contribute to the therapy refractoriness of LSCs,
which may be considered their clinically most relevant
property [11].
Like other malignant diseases, AML is the result of
somatically acquired genetic lesions, e.g., numerical and
structural chromosome aberrations, copy number alter-
ations (CNAs), uniparental isodisomies (UPDs), small in-
sertions or deletions (indels), and single nucleotide
variants (SNVs)[5, 14–19], which accumulate in LSCs
and consequently are present also in their progeny. In
addition, epigenetic and transcriptional changes contrib-
ute to leukemogenesis [5, 15–17, 20–25]. Aberrations
present in the malignant cells of different patients (i.e.,
recurrent alterations) are assumed and, in many cases,
have been shown to act as drivers of leukemogenesis.
They serve as useful prognostic markers [14–19, 26] and
additionally may represent suitable targets for rationally
designed therapies [5, 8, 9, 27–29].
Recently, next generation sequencing-based investiga-
tions have yielded important novel insights into the mo-
lecular pathogenesis of AML. They have uncovered
previously unknown recurrent aberrations in this disease
entity [30, 31] and revealed that AML genomes on average
contained several hundred mutations in non-repetitive
regions but only low two-digit numbers of mutations
with predicted translational consequences, which is
substantially fewer than in most solid tumor genomes
[17, 32–34]. An even smaller number of mutations per
patient affected suspected leukemogenic driver genes.
These appeared to accumulate in a specific order, in
that mutations in genes coding for epigenetic regulators
and chromatin remodeling factors tended to occur early,
while mutations in genes coding for transcription factors
and signaling molecules typically arose late in the process
of leukemogenesis [19, 35–38]. Remarkably, early muta-
tions were also found in phenotypically and functionally
normal HSCs in a substantial proportion of AML patients,
and often persisted in remission [35–39]. Furthermore, a
subset of healthy individuals exhibited low levels of
clonal hematopoiesis that could, but did not necessar-
ily, involve early leukemogenic driver mutations [40–42].
The frequency of this phenomenon, termed “clonal
hematopoiesis of indeterminate potential” (CHIP), in-
creased strongly with age, and the affected persons carried
a substantially increased, albeit in absolute terms still low,
risk to develop hematological malignancies [40–43]. Over-
all, a picture emerges in which HSCs accumulate muta-
tions during the lifetime of an individual. Some of these
lesions lead to the formation of preleukemic stem cells,
which have a proliferation and/or survival advantage but
are still able to give rise to functional, differentiated pro-
geny. Additional mutations, often in genes coding for sig-
naling proteins or transcription factors, are required to
promote the transformation to LSCs and, consequently,
overt AML [44, 45]. This mutational history is reflected in
the clonal composition of AML samples. Based on the dis-
tributions of variant allele frequencies (VAFs) of individual
mutations, diagnostic AML samples were found to harbor
1–4 cellular clones whose size exceeded the detection
threshold of the employed methods. In oligoclonal cases, a
founding clone contained the age-related and pathogeneti-
cally probably largely irrelevant majority of the sequence
variants, as well as the early leukemic driver mutations, at
VAFs indicating their presence in almost all cells of the
sample. One to three subclones harbored additional muta-
tion clusters, including late driver mutations, at lower
VAFs [17, 32–34]. Further minor subpopulations were
often detectable upon application of more sensitive
methods [36, 46, 47].
The majority of genetic and molecular studies on AML
have focussed on the characterization of alterations
present at the time of diagnosis, yet, as outlined above, a
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large proportion of AML patients with primarily respon-
sive disease ultimately die due to relapse with refractory
leukemia. The survival of stem cells, whose regrowth leads
to disease recurrence, is assumed to be due in part to pro-
tective effects of the microenvironment [48–50] and in
part to cell autonomous mechanisms elicited by molecular
alterations in the stem cells themselves, as has been im-
pressively demonstrated in the case of acute lymphoblastic
leukemia [51, 52]. Such molecular changes may already
have been present in a (sometimes very small) subset of
stem cells at presentation, or may have emerged during,
and even as a consequence of the mutagenic effects of, cy-
tostatic therapy [34, 39]. For specific lesions to qualify as
candidate drivers of relapse, they should (1) be recurrently
gained at this disease stage (for the purpose of this review,
the definition of “gain” or “acquisition” at relapse includes
a strong increase in abundance), (2) not be lost at relapse
in other patients (albeit cells carrying a molecular alter-
ation capable of conferring therapy resistance might be
outcompeted by cells with an even stronger selective ad-
vantage in a small number of cases), and (3) either not be
observed at diagnosis, or be associated with poor response
to therapy if present at this stage. A still limited but
rapidly growing number of investigations have assessed
genetic, epigenetic, and gene expression differences in
AML cells from the times of diagnosis and relapse
(Fig. 1). In order to further explore mechanisms that
may lead to therapy resistance and relapse in AML,
these studies are summarized in this review, and data
from them are compiled into comprehensive tables
(Table 1, Additional file 1: Table S1, Additional file 2:
Table S2 and Additional file 3: Table S3).
Cytogenetic changes between diagnosis and
relapse of AML
Cytogenetics yielded the first insights into leukemia
genetics, and cytogenetic analyses were the first to
compare leukemic samples from the times of presenta-
tion and recurrence. During progression to relapse, kar-
yotypes developed following five major patterns: no
change (stability), acquisition of additional alterations
(progression or evolution), loss of alterations (regression
or devolution), progression combined with regression, and
the emergence at recurrence of karyotypes that were unre-
lated to those found at presentation. Studies including
45–168 patients with AML observed a stable karyotype in
39-62% of them [53–56]. Among the different types of
karyotypic instability, evolution was present in 25–46% of
all patients, and devolution, evolution + devolution, and
unrelated karyotypes at relapse were observed in 13–22,
5–12, and 2–8% of cases with an abnormal karyotype at
diagnosis, respectively [53, 54, 56]. In one patient cohort,
normal karyotypes appeared to be more stable than abnor-
mal karyotypes [54], while in another, normal karyotypes
and abnormal karyotypes exhibited similar frequencies of
evolution, and only patients with prognostically unfavor-
able changes at diagnosis exhibited significantly increased
rates of instability [56]. In fact, even normal karyotypes
can become highly unstable and develop into complex
karyotypes during disease progression [53]. An interesting
and potentially clinically relevant question is whether and
how often karyotypic evolution leads to a switch in cyto-
genetic risk group. While in one study this was the case
for only 6/44 patients (14%; intermediate to unfavorable in
all cases) [56], in another report, a transition from favor-
able to intermediate and from intermediate to unfavorable
cytogenetics was found in 2 (12%) and 8 (47%) of 17 pa-
tients with karyotypic changes, respectively [55].
Aberrations newly acquired at relapse in a recurrent
manner are summarized in Fig. 2 and Additional file 1:
Table S1A, those repeatedly lost at relapse are listed in
Additional file 1: Table S1B. As is evident from Additional
file 1: Table S1A, each of the above cited studies found sev-
eral recurrently gained aberrations, but only few of these
were concordant between the different reports. Among the
latter were trisomy 8, trisomy 21, and deletions affecting
the long arm of chromosome 9. However, the trisomies
were also lost at relapse in several cases (Additional file 1:
Table S1B), and neither they nor del(9q) were unequivo-
cally associated with a particularly poor response to ther-
apy when present at diagnosis [18, 19, 57, 58], thus
questioning their potential roles as drivers of therapy resist-
ance and relapse. Deletions of chromosome bands 11p13
and 11q23 were also recurrently gained at relapse in more
than one study. They were also reported in diagnostic sam-
ples [59–61], but to the best of authors’ knowledge, their
prognostic significance is not known. Any conclusion
about their potential contribution to therapy refractoriness
and relapse therefore has to await further investigations. In
contrast, deletions affecting the long arms of chromosomes
5 and 7 were not only recurrently acquired at relapse
(Additional file 1: Table S1A, Fig. 2) but also associated
with a poor outcome when present already at diagnosis
[19, 62], making them potentially interesting candidates for
lesions with a role in therapy resistance and disease
recurrence.
Some studies also investigated possible associations of
karyotypic changes between diagnosis and relapse, or of
chromosome aberrations present at relapse, with various
outcome parameters. Two independent studies, includ-
ing 67 and 56 patients, respectively, reported that the
duration of first remission (CR1), or the time from diag-
nosis to first relapse (TTR), did not differ significantly
between patients with a normal karyotype at both diag-
nosis and relapse and patients who progressed from a
normal to an abnormal karyotype [54, 56]. For patients
with an abnormal karyotype at diagnosis, however, the
length of CR1 was found to be independent of
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karyotypic stability in a cohort of 101 patients [54], while
TTR was reported to be significantly shorter in cases
with evolution of an abnormal karyotype or with an un-
related abnormal karyotype at relapse, compared to that
in cases with regression or no alteration of an abnormal
karyotype in a group of 61 patients [56]. Investigating
the response to treatment for first relapse, Estey et al.
found no difference regarding the likelihood to achieve
CR2 or its duration between 47 patients who exhibited a
normal karyotype at both diagnosis and relapse and 20
patients who progressed from a normal to an abnormal
karyotype [54]. In contrast, Wang et al. reported that
event-free survival (EFS) after relapse was significantly
shorter in 30 patients with a normal karyotype at diagno-
sis and an abnormal karyotype at relapse than in 30
patients with a stable normal karyotype [63]. Similarly,
among 45 patients with various karyotypes at diagnosis,
the overall response to treatment for first relapse was
significantly lower in the 17 cases with an unstable karyo-
type, and karyotypic stability was the only independent
predictor of overall survival (OS) and EFS in multivariate
analyses [55]. Finally, Kern et al., investigating a cohort of
120 patients, found that only karyotype at relapse, but not
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Fig. 1 Genetic and molecular events investigated for possible changes between diagnosis and relapse of AML. A diagram representing clonal
evolution in a hypothetical patient with AML is shown in the top panel. The other panels represent genetic and molecular alterations between
diagnosis and relapse of AML that are discussed in this article; methods used to investigate these aberrations are indicated to the left of the
respective panels. HSCs hematopoietic stem cells, CR complete remission, transloc translocation, SNP single nucleotide polymorphism
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Table 1 Gains and losses of mutations in known leukemia driver genes at relapse of AML
Total number
of patients
Age group Genetics at
diagnosis
Number of patients
with gain of mutation
Number of patients
with loss of mutation
Reference
FLT3-ITD
Total 492 38 25
28 A 1 1 [65]
28 A 6 1 [77]
34 A 2 3 [76]
108 A 8 1 [81]
31 A 1 2 [85]
53 A NPM1m 9 3 [69]
80 A, P 5 4 [79]
44 A, P 2 5 [80]
23 P 2 1 [84]
63 P 2 4 [83]
FLT3-TKD
Total 385 10 24
34 A 1 3 [76]
120 A 6 8 [82]
31 A 0 1 [85]
53 A NPM1m 0 10 [69]
53 A, P 0 1 [79]
44 A, P 2 0 [80]
50 P 1 1 [83]
NPM1
Total 299 0 9
28 A 0 0
[65]
34 A 0 3 [76]
53 A NPM1m n.a. 5 [69]
70 A, P NPM1m n.a. 0 [124]
46 P 0 0 [125]
68 P 0 1 [83]
DNMT3A
Total 231 1 2
28 A 0 0 [65]
34 A 0 0 [76]
116 A 0 1 [87]
53 A NPM1m 1 1 [69]
CEBPA
Total 241 2 5
28 A 1 1 [65]
34 A 0 2 [76]
149 A, P 0 2 [86]
30 P 1 0 [83]
IDH2
Total 236 0 1
28 A 0 0 [65]
34 A 0 0 [76]
121 A 0 0 [126]
53 A NPM1m 0 1 [69]
IDH1
Total 115 4 2
28 A 0 0 [65]
34 A 0 0 [76]
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of relapsed disease. Furthermore, even though an unfavor-
able karyotype at diagnosis was associated with shorter
OS and EFS as compared to intermediate or good risk
karyotypes, the differences were even stronger when
considering the karyotype at relapse [56]. Due to the
heterogeneity of these studies regarding patient popula-
tions as well as influence and outcome parameters, a clear
understanding of the roles of karyotypic stability and of
karyotype at relapse with respect to the prognosis of AML
will have to await additional studies.
Table 1 Gains and losses of mutations in known leukemia driver genes at relapse of AML (Continued)
53 A NPM1m 4 2 [69]
NRAS
Total 106 8 12
19 A 2 3 [77]
34 A 1 0 [76]
53 A NPM1m 5 9 [69]
KRAS
Total 62 1 1
28 A 0 1 [65]
34 A 1 0 [76]
RAS
Total 75 6 8
23 P 2 1 [84]
52 P 4 7 [83]
TP53
Total 104 3 1
28 A 0 1 [77]
23 A 2 0 [78]
53 A NPM1m 1 0 [69]
WT1
Total 104 14 0
23 P 3 0 [84]
42 P 5 0 [83]
39 P 6 0 [127]
ASXL1
Total 81 2 0
28 A 0 0 [65]
53 A NPM1m 2 0 [69]
KIT
Total 35 0 0
27 P 0 0 [83]
8 P CBF 0 0 [128]
TET2
Total 62 0 0
28 A 0 0 [65]
34 A 0 0 [76]
MLL-PTD
34 A 0 0 [76]
PTPN11
23 P 0 1 [84]
RUNX1
28 A 1 1 [65]
The total number of investigated patients, patient age group, genetics at diagnosis in studies based on selected samples, the number of patients with gain or loss of mutation
in the respective gene, and the corresponding references are listed. This table summarizes mutations determined by small scale targeted sequencing approaches. Gains and
losses of mutations in these genes were also found through next generation sequencing-based methods, as summarized in Additional file 3: Table S3A and B
A adult, P pediatric, n.a. not applicable, NPM1m AML with NPM1 mutations, CBF AML with core-binding factor rearrangements
Total number
of patients
Age group Genetics at
diagnosis
Number of patients
with gain of mutation
Number of patients
with loss of mutation
Reference
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Changes in copy number alterations and
uniparental isodisomies between diagnosis and
relapse of AML
Several studies employed single nucleotide poly-
morphism (SNP) arrays to compare acquired CNAs
(aCNAs; i.e., gains and deletions), and copy neutral
losses of heterozygosity (i.e., UPDs) between samples
collected from AML patients (n = 11–53) at presenta-
tion and recurrence. aCNAs/UPDs were rather infre-
quent in AML, with an average of <1–~5 such events
per sample, but their number increased significantly
from diagnosis to relapse [64–69]. In contrast, a
whole exome sequencing (WES) study on 20 cytoge-
netically heterogeneous pediatric AML patients found
that aCNAs/UPDs were gained and lost at relapse at
similar rates, and only about 20% of these events per-
sisted between presentation and recurrence [70].
Whether the discrepancies between the WES and the
array-based studies are due to differences in method-
ologies and/or patient populations remains to be
established.
Some aCNAs/UPDs affecting specific chromosomal
regions were acquired at relapse in a recurrent manner
(Fig. 2, Additional file 2: Table S2A), but, as with aberra-
tions detected via cytogenetic analysis, only a limited
number of these were identified as recurrent in more
than one study. Among these are del(2q33.3), del(3p14.2),
del(4q22.1), del(12p13), UPD(13q), and del(17p13)
(Additional file 2: Table S2A). Deletions of chromosome
bands 2q33, 3p14, and 4q22 have been reported infre-
quently at diagnosis of AML [59], and to the best of the
authors’ knowledge, little if any information is available
regarding their potential prognostic significance.
Del(12p13) was frequently observed in diagnostic sam-
ples from patients with a complex karyotype, which is
per se indicative of a poor prognosis, and candidate
tumor suppressor genes have been mapped to the
affected region [71]. Acquisition of UPD(13q) at relapse
in most cases transformed a FLT3 internal tandem
duplication (ITD) that had existed in a heterozygous
state at diagnosis to homozygosity [64]; the presence of
comparable lesions already at diagnosis was associated
with poor responsiveness to therapy [72, 73]. Finally,
deletion of the tumor suppressor gene TP53 in chromo-
some band 17p13 was frequent in cytogenetically complex
diagnostic samples and independently predicted poor
survival on the background of both complex and non-
complex karyotypes [19, 74]. Acquisition of a comparable
lesion, namely, monosomy 17, at relapse was also re-
peatedly observed by cytogenetic analysis (Additional
file 1: Table S1A). UPD(13q), del(17p13), and possibly
some of the other abovementioned aberrations can
therefore be considered interesting candidates for a role in
therapy resistance and relapse.
Changes in the mutational status of known
leukemia driver genes between diagnosis and
relapse of AML
SNVs or indels affecting genes that are recurrently mu-
tated in diagnostic AML samples are considered drivers
of the leukemogenic process, may be predictive of
outcome, and, if stable during the course of disease, may
serve as markers for disease monitoring [18, 19, 75].
Furthermore, such mutations, if newly acquired at re-
lapse, might contribute to therapy resistance associated
with this stage, especially if their presence at diagnosis is
also associated with poor outcome, as is the case, e.g.,
for the FLT3 internal tandem duplication (FLT3-ITD)
and for mutations in ASXL1, DNMT3A, and RUNX1
[18, 19]. For these reasons, a number of studies have
investigated the presence or absence of such mutations
at different stages of AML. As summarized in Table 1,
FLT3-ITD and FLT3 tyrosine kinase domain (FLT3-TKD)
mutations, as well as RAS, TP53, WT1, and IDH1
mutations were recurrently gained at relapse of AML
[65, 69, 76–84]. Furthermore, the FLT3-ITD/wild-type
ratio, which represents an additional prognostic factor,
was increased at relapse in several patients [81, 85].
However, all of these mutations, except for those in TP53,
were also recurrently lost at relapse (Table 1, Additional
file 3: Table S3B) [65, 69, 76, 77, 79–84, 86, 87], which
makes a strong contribution to therapy refractoriness at
disease recurrence less plausible.
SNVs/indels can be measured with higher sensitivity
than molecularly poorly characterized cytogenetic aber-
rations or CNVs/UPDs. Some authors therefore asked
whether their new appearance at relapse was due to the
expansion of a cell population present at diagnosis but
too small for detection with standard methods, or to ac-
tual de novo mutation. While a radioactive PCR assay
detecting the FLT3-ITD with a sensitivity of 1/200 sup-
ported the latter possibility in 3/3 investigated patients
[80], patient-specific FLT3-ITD qRT-PCR assays with a
sensitivity of 10−4–10−5 provided evidence for the former
scenario in 4/6 tested patients [47]. Similarly, mutations
present at relapse and undetectable in the leukemic bulk
at diagnosis could be traced back to flow sorted subpop-
ulations of 5/7 presentation samples [46]. Targeted rese-
quencing (median coverage, 20.000) in 3 patients who
relapsed within 1 year revealed that some of the putative
relapse-specific mutations were present at low ratios
already at diagnosis, while others remained undetectable
even at this level of sensitivity [36]. In contrast, in 5 pa-
tients relapsing after more than 5 years, none of the
relapse-specific mutations was detected at diagnosis
using targeted resequencing at a sensitivity of 0.001 [38].
FLT3-ITD alleles have varying lengths and insertion
sites, facilitating detailed molecular analyses that re-
vealed complex and highly dynamic clonal patterns.
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Patients displayed up to three different alleles at a
given time point during the course of their disease. In
some cases, only one out of two or three mutations
present at diagnosis was preserved at relapse and
could be derived from either the major or a minor
clone present at diagnosis. Some patients lost one of
their diagnostic alleles at relapse and concomitantly
acquired a new one. Others had only wild-type alleles at
diagnosis but relapsed with two different ITD alleles, or
had one mutation type at diagnosis and relapsed with
the same allele in addition to a newly gained one [81,
85, 88]. Similarly, complex patterns of losses and gains
of mutations were reported for the RUNX1 gene [89].
Single cell analysis further underscored the substantial
clonal diversity in AML: in samples with two different
FLT3-ITD alleles, single cells either had wild-type alleles
only, or harbored one of the two mutant alleles in a
homozygous or a heterozygous state but, interestingly,
no single cell was compound heterozygous for the two
ITD alleles. In contrast, in samples containing both
FLT3 and NPM1 mutations, these occurred in all
possible combinations [90].
Fig. 2 Circos plot summarizing genetic aberrations recurrently acquired at relapse in adult patients with non-APL AML. Inner circle, unbalanced
cytogenetic aberrations newly acquired at relapse in at least 2 patients [53–56, 63, 68, 122]; middle circle, CNAs and UPDs newly acquired at relapse in
at least 2 patients [64–69]. Within each type of aberration, overlapping lesions were considered recurrent events unless an aberration was reported only
in 1 patient and became recurrent due to the same type of aberration affecting the corresponding entire chromosome in another single patient. For
high patient numbers, different scales were used and patient numbers color-coded as indicated in the graphical legend. Outer circle, genes affected by
SNVs or indels in a relapse-specific manner in at least 2 patients according to next generation sequencing-based studies [34, 36, 38, 39, 68, 95, 96]. The
plot was constructed using the R package “circlize” [123]. Genomic positions of genes and chromosome bands were retrieved from the UCSC
genome browser, human genome version hg19. Detailed data are provided in Additional file 1: Table S1A, Additional file 2: Table S2A, and
Additional file 3: Table S3A. These also include studies containing exclusively pediatric patients or patients with APL, which were not considered for this
figure. Recurrently gained aberrations are shown in this graph irrespective of whether or not they were recurrently lost in other patients; information
about recurrent loss at relapse is provided in Additional file 1: Table S1B, Additional file 2: Table S2B, and Additional file 3: Table S3B
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Some authors also related mutational instability, or
mutation status at relapse, to outcome parameters. In a
study on 23 pediatric AML patients of all cytogenetic
risk categories, cases with a mutational shift in FLT3,
RAS, PTPN11, and/or WT1 had significantly worse OS
than those with mutational stability [84]. FLT3-ITD and
TP53 mutations at disease recurrence were significantly
associated with short survival after relapse among 28
adult patients with cytogenetically heterogeneous AML
[77]. Perhaps even more remarkably, in a cohort of 80
pediatric and adult patients with various karyotypes,
FLT3-ITD status at relapse was associated with TTR
more significantly than the same molecular feature at
diagnosis [79], and among 69 patients with pediatric
AML and mixed cytogenetics, FLT3-ITD and WT1 mu-
tations at relapse, but not at presentation, were signifi-
cantly associated with shorter OS, with FLT3-ITD status
at relapse confirmed as an independent prognostic par-
ameter in multivariate analyses [83]. Even though it has
to be kept in mind that the inclusion only of relapsing
patients led to a skewing of the patient population at
diagnosis in these studies, their results suggest that muta-
tions existing at presentation in subpopulations too small
for detection with standard methods, or even acquired
only during therapy, may have a more important impact
on outcome than the genotype of the bulk leukemic
population at diagnosis. If this notion can be confirmed
in larger patient cohorts, it may have important impli-
cations for the routine assessment of prognostically
relevant mutations at diagnosis.
Next generation sequencing to investigate SNVs
and indels during the evolution of AML
In a seminal study published in 2012, Ding et al. estab-
lished several important concepts regarding the evolution
of AML from presentation to recurrence [34]. Matched
constitutional (skin), diagnostic, and relapse samples from
8 adult patients with AML (7 with a normal karyotype, 1
with t(15;17)) were subjected to whole genome sequencing
(WGS), followed by validation of variants through deep
sequencing of captured targets. An average of 539 somatic
mutations and structural variants in the non-repetitive re-
gions of the genome, of which 21 affected protein coding
regions, were identified per case. The majority of the mu-
tations were shared between diagnosis and relapse, and
only relatively small proportions were gained or lost at the
latter stage [34]. All patients harbored between one and
four mutation clusters at diagnosis, and all acquired add-
itional mutations at relapse, although remarkably in three
cases, none of these mutations were non-synonymous.
Two major patterns of clonal evolution were observed: in
3 patients, the dominant clone at diagnosis gained add-
itional mutations and evolved into the relapse clone, while
in 5 patients, one or two minor subclone(s) carrying most,
but not all, of the mutations present at diagnosis acquired
new sequence variants and expanded at relapse [34].
Among the relapse-specific mutations, the proportion of
transversions was significantly increased, suggesting that
chemotherapy affected the mutation pattern and, through
its mutagenic effects, may have directly contributed to
therapy resistance [34].
Subsequent reports employing whole exome sequencing
(WES) (usually followed by validation through independ-
ent methods) and/or targeted resequencing confirmed
and extended these findings. Two WES studies, restricted
to adult patients with FLT3-ITD-positive AML (n = 13)
and core-binding factor AML (n = 10), respectively, found
numbers of exonic mutations comparable to those in
the earlier investigation. Again, the majority of these
mutations persisted during disease progression, while
some were specific to either diagnosis or relapse [39, 68].
These investigations also corroborated the increase in the
proportion of transversions among relapse-specific muta-
tions, as well as the previously described patterns of clonal
evolution [39, 68]. As an extension to the latter aspect,
some studies suggested that relapse clones may also evolve
from preleukemic HSCs, thus uncovering another poten-
tial cellular origin of disease recurrence [36, 38, 69]. Along
similar lines, the relatedness between leukemic clones at
diagnosis and relapse decreased with increasing TTR: tar-
geted resequencing of 122 recurrently mutated genes in
paired samples from 22 patients with cytogenetically het-
erogeneous AML revealed a significantly larger number of
retained mutations in patients relapsing after <3 years
than in those relapsing after >5 years, while the number of
gained or lost lesions behaved in the opposite manner.
Nevertheless, no relation between either TTR or the ex-
tent of clonal evolution and response to therapy for recur-
rent disease was observed in this study [38]. This may be
due to the small size of the patient cohort, however, be-
cause the duration of CR1 is a well-established prognostic
parameter in relapsed AML [2].
Three studies applied WES to pediatric AML, two
including each 4 [91, 92], and the third 20 [70], pa-
tients with variable karyotypes. Their findings essen-
tially paralleled those in adult AML. As an interesting
extension, Farrar et al. reported a median of 3.5 and 8
non-synonymous mutations in patients <2 and 2–
17 years old, respectively, supporting the assumption
that the majority of mutations present in leukemic
cells are a result of aging, rather than causal contribu-
tors to tumorigenesis [70].
Due to its different biology and treatment modalities
[8, 9, 93], mutational patterns in APL might be expected
to differ from those of other AML cases. Indeed, in 222
partially paired samples from 200 patients with pediatric
and adult APL, targeted resequencing showed that both
at diagnosis and at relapse, the frequencies of some of
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the known AML driver mutations were distinct from
those in the 180 diagnostic non-APL AML samples in
the The Cancer Genome Atlas cohort [17, 94]. At recur-
rence, mutations in PML and RARA were repeatedly
observed in patients treated with arsenic trioxide and all-
trans retinoic acid, respectively [94]. WES on paired
samples from 8 patients with a median age of 22.5 years
revealed an average of 9.6 non-synonymous mutations per
patient. As in non-APL AML, mutational load did not
change significantly from diagnosis to relapse. Remark-
ably, in 2 of 8 patients, no SNVs/indels but only the
PML-RARA fusion persisted between presentation and
recurrence [94], suggesting that it was an early event
in these cases.
In an approach somewhat different from the above
discussed studies, Kim et al. used WES to track the
course of disease of a patient presenting with cytogeneti-
cally normal AML at the age of 36 over 9 years, during
which he experienced four CRs and four relapses [95].
Two findings of this study appear particularly note-
worthy: Firstly, a single cellular clone constituted the
leukemic population from relapses two through four,
raising the question which (molecular) events caused
therapy resistance at the final relapse (the unconvincing
candidates captured by WES were loss of mutations in
OR2T12 and NPM1, gain of a synonymous mutation in
VTN, and a moderate increase in the VAF of a splicing
mutation in TMEM63C). Secondly, a clone containing
the DNMT3A-R882H mutation of the founding clone,
along with five additional variants, expanded strongly
during CRs two to four to reach VAFs of up to 50%
(indicating monoclonality) and decreased, but was not
eliminated, during subsequent relapses [95]. Similar
observations were reported for 5 of 15 adult de novo
AML patients investigated by WES: clones defined by
somatic variants not present in the AML clones yet
detectable at VAFs <1% at diagnosis, expanded 30–
150-fold within 1–2 months after initiation of therapy
and persisted at similar or increasing levels through
observation periods of 161–544 days [96]. The clinical
implications of this phenomenon are presently
unclear.
A unique subgroup among patients with AML are
those with familial disease due to predisposing germ line
mutations, e.g., in CEBPA. In a cohort comprising ten
pedigrees with this condition, patients presented with
AML at a median age of 24.5 years [97]. WES on nine
leukemic samples identified on average 17.8 tumor-specific
mutations with predicted translational consequences per
patient [97], comparable to the numbers in sporadic AML.
The somatic mutations affecting the second CEBPA allele,
as well as additional SNVs identified by WES, were discord-
ant between diagnosis and recurrence, suggesting that in
this condition, recurrences more commonly represent new
leukemic episodes rather than relapses of the original dis-
ease, in agreement with the clinical observation that they
frequently retain therapy sensitivity [97].
In summary, next generation sequencing-based methods
have yielded important insights into the biology and
evolution of AML. However, other than in T cell acute
lymphoblastic leukemia (T-ALL), where activating
mutations in the gene encoding the drug inactivating
5′-nucleotidase NT5C2 were acquired in almost one
fifth of patients at disease recurrence [51, 52], no strik-
ing candidate genes, mutations in which would be
recurrently gained and rarely or never lost at relapse of
AML and plausibly contribute to therapy resistance,
were so far identified (Additional file 3: Table S3A, B).
As possible exceptions, mutations in ASXL1, SETBP1,
and ZRSR2 were recurrently gained but not recurrently
lost at relapse (Table 1, Additional file 3: Table S3A, B)
and were associated with a poor outcome when present
at diagnosis [18, 19, 98]. However, the numbers of pa-
tients who acquired mutations in these genes were
small (two to four cases; Additional file 3: Table S3A).
Even though it remains possible that application of un-
biased methods like WES or WGS to larger, more
homogeneous patient cohorts will lead to the identifica-
tion of (additional) candidate driver mutations of re-
lapse, a universal role of SNVs or indels—at least in
their “classical” mode of action—in the evolution of
therapy resistance is also questioned by observations
that disease can recur in a refractory manner without
the acquisition of additional non-synonymous mutations
[34, 92, 95]. Therefore, mutations with consequences
other than a change in primary protein structure, e.g.,
regulatory variants, and/or molecular events not cap-
tured by genome sequencing methodologies, e.g., epi-
genetic or gene expression changes, may play important
or even dominant roles in the development of therapy
resistance and relapse.
Changes in the methylation of gene regulatory
regions between diagnosis and relapse of AML
Alterations in DNA methylation are common in myeloid
malignancies, and demethylating agents play a role in
their clinical management [99]. To explore the relevance
of changes in DNA methylation at relapse of AML, Li et
al. performed genome-wide methylome analysis through
Enhanced Reduced Representation Bisulfite Sequencing
(ERRBS) on paired diagnosis and relapse samples from
138 cytogenetically heterogeneous patients; 48 of these
were additionally subjected to WES [100]. Eloci were de-
fined as sequences of four consecutive CpGs exhibiting a
significant shift of the entropy of their methylation sta-
tus as compared to normal bone marrow. While eloci
were significantly overrepresented at CpG islands and
promoters at diagnosis, they were enriched in intronic
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and intergenic regions at relapse. Neither overall muta-
tion burden nor the presence of mutations in specific
genes (e.g., epigenetic modifier genes) was significantly
associated with levels of eloci per million loci. However,
in contrast to somatic mutation load, high eloci per mil-
lion loci values at diagnosis were significantly associated
with shorter TTR, a relation that was most significant
for promoter-associated eloci [100].
Kröger et al. focussed on nine genes whose CpG
islands had previously been shown to be hypermethy-
lated in primary and cultured malignant hematopoietic
cells, and probed them by bisulfite pyrosequencing in
paired diagnostic and relapse samples from 30 patients
with cytogenetically heterogeneous AML [101]. The me-
dian number of methylated genes increased from four at
presentation to six at recurrence, and a significant in-
crease in methylation density at relapse was observed for
the CpG islands of the CDH13, NPM2, PGRA, HIN1,
SLC26A4, and CDKN2B genes [101]. Methylation of the
CDKN2B CpG island also increased significantly from
48/77 (62%) cases at presentation to 30/36 (83%) at
relapse of APL [102].
Changes in the expression of protein coding and
microRNA genes between diagnosis and relapse
of AML
Altered expression of certain genes contributes to
leukemogenesis, and the mRNAs levels of single genes
as well as the presence of specific multi-gene expression
signatures at diagnosis are predictive of outcome in
AML [20–22, 103–105], raising the possibility that
recurrent gene expression changes between diagnosis
and relapse may also contribute to therapy resistance at
the latter stage. Some studies suggested that single genes,
selected for investigation based on prescreening data from
independent experimental systems, e.g., TGM2, CDK1,
miR-331-5p, and miR-27a, were significantly deregulated
between diagnosis and relapse of AML [106–108]. Others
pursued large-scale approaches to identify genes
differentially expressed between the two disease stages
[84, 109–111]. Even though these investigations, per-
formed on limited numbers of only partially matched and
mostly cytogenetically heterogeneous samples, identified
genes differentially expressed between diagnosis and re-
lapse, correction for multiple hypothesis testing was either
not performed or not passed by any of the probed genes.
In contrast, Hackl et al., restricting their analyses to cyto-
genetically normal AML and using 11 paired diagnostic
and relapse samples for genome-wide gene expression
profiling, discovered 536 and 551 genes that were up- and
downregulated at relapse, respectively, at a false discovery
rate (FDR) of <10% [112]. Supporting the notion that spe-
cific gene expression patterns may contribute to therapy
resistance in relapsed AML, previously defined diagnostic
expression signatures associated with poor outcome in
this disease [21, 22, 113] and/or with LSCs [13] were sig-
nificantly enriched in the relapse-associated gene expres-
sion profile [112]. Consistent with these findings, Ho et al.
recently reported a 9- to 90-fold increase in the frequency
of functional LSCs, measured by limiting dilution trans-
plantation into NSG mice, in relapsed versus diagnostic
samples from 5 patients with AML [114].
In addition to protein-coding genes, microRNA genes
may be differentially expressed between diagnosis and
relapse of AML: a Taqman low-density array screen on
six paired samples from pediatric patients with MLL re-
arrangements uncovered 53 microRNAs that were up-,
but none that were down-, regulated at relapse at an
FDR of <10%, among them the miR-106b~25 cluster.
The expression pattern of about half of the tested micro-
RNAs could be confirmed by qRT-PCR in the original,
plus eight additional, sample pairs [115].
While all of the abovementioned studies measured
gene expression in a static manner, expression changes
elicited by chemotherapeutic drugs may also play a role
in the response to them. Therefore, Fisser et al. searched
for genes that were induced by cytostatics in the human
myeloid cell line U937. CADM1 was upregulated upon
exposure to cytosine arabinoside, daunorubicin, or
etoposide, and its experimental expression in U937 cells
led to an increase in the proportion of apoptotic cells
[116]. Corroborating its suspected role in chemotherapy
induced cell death, CADM1 was upregulated in response
to in vitro exposure to cytosine arabinoside in 3/3
primary AML samples from the time of diagnosis, but in
none of the matched relapse samples [116].
Miscellaneous molecular parameters that changed
between diagnosis and relapse of AML
The following chapter briefly summarizes several studies
that compared molecular parameters not readily attrib-
utable to any of the above categories between diagnosis
and relapse of AML. In the first of these, Shlush et al.
inferred the number of cell divisions that had occurred
in a cell population from single cell microsatellite data
and concluded that in two investigated patients with
AML, proliferative activity was higher at diagnosis than
at relapse [117]. Another report, based on analyses of
the mutation and promoter methylation status of the
MSH2 and MLH1 genes in unpaired diagnostic, relapsed,
and refractory samples from 53 pediatric and adult
patients with AML, suggested that aberrations affecting
mismatch repair genes were significantly more frequent in
refractory/relapsed samples than in diagnostic ones
(12/25 versus 6/28) [118]. Zhou et al. measured various pa-
rameters related to oxidative stress in paired presentation
and recurrence samples obtained from 102 adult patients
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with AML, as well as in an equal number of age-matched
healthy controls, and concluded that relapse was associated
with an increase in oxidative stress [119]. Finally, mitochon-
drial priming, measured via molecular indicators of pro-
grammed cell death elicited by proapoptotic BH3-only
peptides and proposed to reflect cellular propensity to
undergo apoptosis in response to appropriate stimuli, was
significantly decreased in relapse samples from six patients
as compared to the matched diagnostic specimens [120].
Conclusions
Based on mutational profiles and clonal dynamics ob-
served in patients with AML, three major pathways to
relapse have been proposed [18, 36, 38, 44, 69] (Fig. 3).
Each of these appears to be taken in a subset of cases.
In patients whose disease follows the first trajectory,
few if any genetic alterations with presumed functional
relevance distinguish relapse from diagnostic samples;
relapse is supposed to be due to the regrowth of an
LSC present already at diagnosis and often follows a
short remission [44]. In patients who nevertheless
experience a longer remission [38, 92, 95], genetic
changes not captured by the methods applied, changes
with less obvious functional consequences (e.g.,
mutations in regulatory regions), and/or epigenetic or
gene expression alterations may contribute to in-
creased therapy resistance at relapse. The second path-
way is reflected by a scenario in which a diagnostic
clone harboring both early (preleukemic) and late
leukemogenic driver mutations reappears with add-
itional, newly gained mutations at relapse; disease
recurrence is therefore due to the evolution of an LSC.
In the third pathway, the diagnostic clone(s) contain(s)
both early and late driver mutations, but only the early,
preleukemic lesions, along with newly acquired mutations,
are present at relapse, consistent with relapse originating
from a preleukemic HSC rather than an LSC.
In some patients with apparent relapse-specific mu-
tations, these could retrospectively be demonstrated to
have been present at very low levels also in the diag-
nostic sample, while in others, they were undetectable
at this time point even with highly sensitive methods
[36, 38, 46, 47], suggesting that they either emerged
only during therapy, or that the stem cells harboring
them were proliferatively inactive at diagnosis. Irre-
spectively, by analogy to the role of genetic and mo-
lecular alterations recurrently present at diagnosis of
AML as drivers of leukemogenesis, lesions recurrently
acquired at relapse can be expected to contribute to
the increased aggressiveness and therapy resistance as-
sociated with this disease stage. In addition, similar to
their counterparts at diagnosis [8, 9, 28, 29], drivers of
relapse represent potential targets for therapeutics for
the treatment of recurring disease, or, ideally, for the
preemptive eradication of initially small therapy-
resistant cell populations so as to prevent the occur-
rence of relapse altogether.
Cure
Relapse due to outgrowth 
of an LSC that carries 
additional non-synonymous
mutations
Relapse due to outgrowth
of a preleukemic HSC 
that carries additional 
non-synonymous mutations
Relapse due to regrowth 




Fig. 3 Different pathways leading to relapse of AML. Gray dots,
age-related, pathogenetically irrelevant passenger mutations; orange
dots, early (pre-) leukemic driver mutations; red dots, late leukemic
driver mutations; bright yellow dots, non-synonymous mutations
newly acquired at relapse. All HSCs are assumed to accumulate
mostly innocuous mutations during aging; only mutations that
would be found as passenger mutations in AML are depicted in
the figure. The figure does not intend to illustrate the duration of
CR, or the presence or absence of minimal residual disease detectable
by routine methods. Dx diagnosis, CR complete remission, LSC leukemic
stem cell, HSC hematopoietic stem cell
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Indeed, the studies summarized above have identified
some aberrations that were newly gained at relapse in a re-
current manner and may plausibly contribute to therapy
resistance at this stage, like deletions of the TP53 gene in
chromosome band 17p13 or point mutations in ASXL1.
However, these lesions were present only in a low single-
digit percentage of the investigated patients. In contrast, in
patients selected for the presence of specific genetic
features at diagnosis, the expression of certain mRNAs or
miRNAs changed between presentation and recurrence in
a statistically significant manner, implying that these
alterations occurred in a large proportion of cases. Further-
more, the mRNA expression profile associated with relapse
of normal karyotype AML was enriched for gene signa-
tures associated with LSCs and with a poor prognosis,
suggesting that some of its member genes may contribute
to therapy resistance at relapse. However, it remains to be
shown whether these gene expression changes are suffi-
ciently uniform among single leukemic cells and sufficiently
stable to represent useful therapeutic targets.
In summary, even though so far only a limited number
of studies has addressed the molecular alterations specif-
ically acquired at relapse of AML, important progress
has been made in understanding the genetics and mo-
lecular biology associated with this largely therapy-
resistant disease stage. Despite of these advances, many
open questions remain. Among these are the extent to
which genetic alterations present at diagnosis and varia-
tions in treatment determine which additional lesions
are able to allow leukemic cells to survive therapy and
regrow at relapse. The possible functional role of muta-
tions without predicted translational consequences war-
rants further exploration [121]. The genetic, epigenetic,
and gene expression alterations between diagnosis and
relapse of AML need to be investigated in larger patient
cohorts, which may need to be more homogeneous in
terms of, e.g., antecedent clonal hematopoiesis of inde-
terminate potential, genetics at diagnosis, and/or treat-
ment. In an ideal scenario, all types of molecular and
genetic alterations would be probed in the same set of
paired samples, and the resulting data integrated to po-
tentially identify different sorts of lesions affecting the
same genes or pathways. Functional analysis of these
candidate genes and/or pathways with respect to their
involvement in therapy resistance is expected to identify
targets for novel therapeutics able to substantially im-
prove outcome in patients with AML.
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